[The effect of mildronate on disorders of the cardiac contractile function in rats caused by an excess of free fatty acids and ischemia].
Oral administration of mildronate, 3-(2,2,2-trimethylhydrazine)propionate, an inhibitor of carnitine-dependent metabolism, in a dose of 50-100 mg/kg for 10 days promoted a rapid restoration of contractility of Langendorf perfused rat heart preparations during postischemic perfusion and protected the rat hearts against inhibition of contractile function resulting from continuous perfusion with palmitic acid. Mildronate inhibits gamma-butyrobetaine hydroxylase, depresses carnitine biosynthesis and reduces carnitine-dependent fatty acid metabolism. The cardioprotective effect of mildronate is particularly manifest upon continuous administration.
Simkhovich
B Z
BZ
Briede
Ia L
IaL
Ozola
R A
RA
Meĭrena
D V
DV
Kalvin'sh
I Ia
IIa
Lukevits
E Ia
EIa
D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology*; D003327:Coronary Disease / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D005230:Fatty Acids, Nonesterified / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D008763:Methylhydrazines / Q000494:pharmacology*; D009200:Myocardial Contraction / Q000187:drug effects* / Q000502:physiology; D019308:Palmitic Acid; D010169:Palmitic Acids / Q000494:pharmacology; D010477:Perfusion / Q000379:methods; D051381:Rats
D002317:Cardiovascular Agents; D005230:Fatty Acids, Nonesterified; D008763:Methylhydrazines; D010169:Palmitic Acids; D019308:Palmitic Acid; C050147:3-(2,2,2-trimethylhydrazine)propionate
Vliianie mildronata na narusheniia sokratitel'noĭ funktsii serdtsa krys, vyzyvaemye izbytkom svobodnykh zhirnykh kislot i ishemieĭ.